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ABSTRACT
INTRODUCTION: Polyphenols (PPs) are plant-derived chemical compounds bearing one or more phenolic 
rings. The most commonly presented dietary PPs include anthocyanins, flavonols, flavanols and phenolic 
acids. Studies have shown that polyphenols exert a variety of actions including antioxidant, anti-inflamma-
tory, antimicrobial, antiproliferative, cancer protective, cardioprotective, lipid-lowering, and glucose-low-
ering. Metabolic syndrome (MetS) is a global health issue associated with an increased risk of cardiovascu-
lar diseases, type 2 diabetes, and certain types of cancer.
AIM: The purpose of this paper is to summarize the current knowledge about the beneficial effects of differ-
ent polyphenols on the clinical manifestations of metabolic syndrome.
MATERIALS AND METHODS: Literature in PubMed, Google Scholar and ScienceDirect has been studied 
and analyzed.
RESULTS: Most data about the beneficial effects of polyphenols is derived from preclinical studies. The clin-
ical trials involving polyphenolic compounds in subjects with MetS are limited, comprise a small number of 
participants, and the duration is short.
CONCLUSION: Numerous studies show promising effects of polyphenols in improving the biochemical and 
clinical abnormalities associated with metabolic syndrome but larger, more precise, better controlled clini-
cal trials are necessary to reveal their benefits in clinical practice.
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Polyphenols (PPs) are plant-derived chemi-
cal compounds bearing one or more phenolic rings. 
They exert different physiological functions in plants 
such as protection against microbial infections and 
UV sunlight as well as attraction of pollinators (1). 
PPs are found in a variety of foods and beverages, no-
tably in berries, grapes, citrus fruits, red fruits, veg-
etables, green tea, coffee, and wine (2-3). In general, 
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amount of free fatty acids (FFAs) in the circulation. 
FFAs reach insulin-dependent tissues and block in-
sulin-mediated glucose uptake through the GLUT-4 
glucose transporter. Hyperglycemia induces hyper-
insulinemia, which in turn increases the absorption 
of sodium and water in the kidneys, stimulates the 
activity of the sympathetic nervous system, and in-
tensifies the insulin resistance. In the liver, increased 
FFA influx activates gluconeogenesis and the pro-
duction of very low-density (VLDL) and low-densi-
ty (LDL) lipoproteins, suppresses that of high-densi-
ty lipoproteins (HDL). Glycogen levels in the muscles 
decrease and lipid levels increase (19).
Metabolic syndrome is also considered as a low-
grade inflammatory state (20). Abdominal (visceral) 
adipose tissue is a source of cytokines, chemokines, 
hormonal elements, and various proteins. Some of 
these products possess an anti-inflammatory activity 
(adiponectin), others—pronounced pro-inflamma-
tory activity (leptin, resistin, inhibitor of plasmino-
gen activator-1, C-reactive protein, interleukins such 
as IL-1, IL-6; TNF-α, fibrinogen, serum amyloid A). 
In MetS, the levels of pro-inflammatory mediators 
are elevated and those of anti-inflammatory media-
tors are decreased (21). Inflammatory molecules pro-
duced by the visceral adipose tissue lead to oxidative 
stress, endothelial dysfunction, hypercoagulability, 
and a further reduction of insulin sensitivity. Taken 
together, all of these events contribute to the develop-
ment of hypertension, hyperglycemia, dyslipidemia, 
as well as other disorders associated with MetS.
PPs are divided into 2 groups: flavonoids and non-
flavonoids (Table 1) (4). The most commonly pre-
sented dietary PPs include anthocyanins (in ber-
ries, red grapes, black currants), flavonols (in berries, 
grapes, apple, tomatoes, onion, tea, red wine), flava-
nols (in blueberries, bananas, apples, peaches, tea), 
and phenolic acids (in fruits, vegetables, coffee) (3-
5). Studies have revealed that they exert antioxidant, 
anti-inflammatory, antimicrobial, antiproliferative, 
cancer protective, cardioprotective, and antidiabet-
ic effects (6-8).
Metabolic syndrome (MetS) is a progressive dis-
order which is associated with development of type 2 
diabetes mellitus (T2DM), cardiovascular diseases, 
non-alcoholic fatty liver disease (NAFLD), obstruc-
tive sleep apnea (OSA), polycystic ovary syndrome 
(PCOS), neuropsychiatric and oncological disorders 
(10-16). Epidemiological studies have shown that in 
subjects with MetS the risk of T2DM is increased 
2-fold, whereas the incidence of cardiovascular com-
plications is increased 4-fold. (17). 
Pathogenesis of Metabolic Syndrome
Consumption of calorie-dense foods and bever-
ages along with physical inactivity contribute to de-
velopment of abdominal obesity, which in turn leads 
to insulin resistance (IR) (18). IR remains the main 
pathogenic mechanism in the development of MetS. 
It is characterized by impaired metabolic effects of 
insulin in different target tissues and organs. In the 
presence of IR, lipolysis in the white adipose tissue 
is activated, which causes the release of an excessive 
Polyphenols
Flavonoids Non-flavonoids
Flavones: apigenin, luteolin, tangeritin, nobiletin, 
sinensetin
Phenolic acids: chlorogenic acid, neochlorogenic acid, 
caffeic acid, ferulic acid, vanillic acid, curcumin
Flavonols: quercetin, myricetin, rutin, morin, kaemferol Stillbenes: resveratrol
Flavan-3-ols (flavanols): catechin, epicatechin, 
epigallocatechin
Lignans: secoisolariciresinol, matairesinol, lariciresinol, 
pinoresinol
Isoflavones: daidzein, genistein
Flavanones: hesperidin, naringenin, eriodictyol
Anthocyanins: cyanidin, malvidin, delphinidin, 
peonidin
Table 1. Classification of polyphenols
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Management of Metabolic Syndrome
The management of MetS includes lifestyle 
modifications, weight loss approaches, and treat-
ment of co-morbidities (22). Lifestyle modifications 
aim at: behavioral changes, calorie restriction, and 
optimal physical activity. Behavioral changes include 
a proper diet (reduced consumption of processed 
foods/pastry/saturated fats, increased consumption 
of fruits, vegetables, whole grains, legumes, fish and 
other seafood), reduced to moderate alcohol con-
sumption, smoking cessation, and cognitive-behav-
ioral therapy. In cases with strict indications, medi-
cations or surgical interventions are used. Pharma-
cological treatment of MetS aims to normalize body 
weight, to improve insulin sensitivity and glyce-
mic control, to lower blood pressure, and to correct 
dyslipidemia. 
Despite different available treatment options, 
there is no definitive treatment of MetS. Therefore, 
there is a growing interest in seeking newer ther-
apeutic agents, including phytotherapeutic ones. 
Studies have shown that PPs might be beneficial in 
patients with MetS.
AIM
In the present paper, the current knowledge 
about the beneficial effects of different polyphenols 
on the clinical manifestations of metabolic syndrome 
is summarized, based on the information from sci-




In the last years, PPs have attracted research in-
terest due to their numerous health benefits. A num-
ber of studies have demonstrated the role of PPs in 
weight control and lipid metabolism. Most data are 
available for catechins, anthocyanins, resveratrol and 
curcumin. 
Catechins. Tea is one of the most common-
ly consumed beverages worldwide. Camellia sinen-
sis leaves are a plant source for different types of 
tea—white, green, oolong or black. Green tea is a 
well-known source of catechins. The most abundant 
one in green tea is epigallocatechin gallate (EGCG) 
(23). Effects of EGCG have been studied in cell cul-
tures, animal and human studies (24). In cell cul-
tures, EGCG inhibits the proliferation and differen-
tiation of adipocytes. It also increases the amount of 
brown adipose tissue (possesses thermogenic and ly-
polytic effects) in the body (25). Adenosine mono-
phoshate (AMP)-activated protein kinase (AMPK) is 
a key regulator of energy metabolism. Its activation 
through AMP results in the upregulation of enzymes 
involved in catabolic pathways and downregulation 
of enzymes involved in anabolic pathways. AMPK 
inhibits acetyl-CoA carboxylase and suppresses fatty 
acid synthesis. On the other hand, it directly inhibits 
the HMG-CoA reductase, a key regulator of hepat-
ic cholesterol synthesis (26). EGCG activates AMPK 
and stimulates fatty acid oxidation in 3T3-L1 cells 
(27). Experimental studies with animals confirmed 
the weight-reducing and antidyslipidemic effects of 
EGCG. In high-fat diet (HFD) models of obesity and 
in knock-out leptin deficient (ob/ob) mice, the ad-
ministration of EGCG reduced the overall body fat 
tissue and body weight, the cholesterol and TG levels, 
the accumulation of TG in the liver and decreased 
the insulin resistance (28-30) Additionally, catechins 
were found to inhibit the intestinal absorption of lip-
ids (26).
A cross-sectional study among 1210 adults who 
consumed green tea at least once a week resulted in 
a significant reduction in the overall body fat and in 
the waist-to-hip ratio (WHR) compared to non-ha-
bitual drinkers (31). Another study with a duration 
of 14 years showed that the continuous consumption 
of catechins decreased the BMI (32).
Anthocyanins. Anthocyanins are water-solu-
ble molecules found in various types of fruits (ber-
ry fruits, chokeberry, grape, black currant, cherry, 
plum) and vegetables (red cabbage, red onion, and 
sweet potato) (33). The beneficial activities of antho-
cyanins can significantly be affected by various food 
processing technologies such as pasteurization, con-
centration and drying (34-35). The anthocyanin cy-
anidin (CND) and its derivatives, such as cyanidin 
3-glucoside (C3G), are the most common anthocya-
nins in nature, giving a dark blue color to a number of 
fruits and vegetables (36). In rats with experimental-
ly-induced MetS, CND reduced the clinical features 
of MetS—such as body weight and serum TG levels 
(37). These effects could be attributed to the activa-
tion of lipoprotein lipase in blood plasma and skele-
tal muscle and the inhibition of the same enzyme in 
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adipose tissue (38). Scazzocchio et al. found that C3G 
exerted insulin-like effects (increased GLUT-4 trans-
location and improved skeletal muscle uptake) by ac-
tivating peroxisome proliferator-activated receptor-
gamma (PPAR-γ). Adiponectin levels also increased. 
This contributed to improvement in insulin sensitiv-
ity (39). Consumption of blueberries, containing the 
anthocyanins peonidin, petunidin or malvidin, im-
proved metabolic parameters in a genetic model of 
obesity (C57BL/6). These anthocyanins are supposed 
to disrupt the mitochondrial proton gradient and 
mitochondrial respiration in adipose tissue, there-
by increasing energy expenditure and reducing the 
weight (40).
Resveratrol. Resveratrol is a stilbene-type of PP. 
Rich in resveratrol are red grapes, red wine, and nuts. 
Its powerful antioxidant and anti-inflammatory ef-
fects have been suggested to be useful in the preven-
tion and treatment of MetS (41). In the 3T3-L1 cell 
line, resveratrol suppressed the activity of fatty acid 
synthase, lipoprotein lipase, decreased TG accumu-
lation, and activated AMPK, thus inhibited lipogen-
esis. It also decreased the expression of nuclear fac-
tor-kappa B (NF-κB) and the levels of the proinflam-
matory interleukin-6 (IL-6) and tumor necrosis fac-
tor-alpha (TNF-α) (42-44). In animals with diet-in-
duced models of obesity, resveratrol resulted in fat 
and weight reduction, decreased fat accumulation in 
the liver, decreased blood lipid levels, and improved 
glycemic control (45-46). However, such favorable 
changes were not achieved in some of the experi-
ments. This is attributed to the duration of the stud-
ies and the dose of resveratrol taken (47-48.). 
A few randomized, placebo-controlled clini-
cal trials with resveratrol supplementation were con-
ducted in order to estimate the effect of this PP on 
body weight. Tome-Carneiro et al. studied the role of 
resveratrol in three large studies and concluded that 
chronic daily consumption of resveratrol improved 
lipid status, modulated the inflammatory response, 
and stimulated fibrinolysis (49-50). However, these 
effects might have also been due to other beneficial 
ingredients in the grapes, used in these studies as a 
resveratrol source. Another randomized study found 
beneficial effects of 30-day consumption of resvera-
trol on metabolism in obese men (decrease of blood 
glucose level, fasting insulin, HOMA-IR, TG, and 
fatty acids) (51).
Curcuminoids. Curcumin is the most impor-
tant PP in Curcuma longa (turmeric), consumed as a 
spice in India and other countries. A number of pre-
clinical and clinical studies have suggested that cur-
cumin and other curcuminoids might be beneficial 
in metabolic disturbances associated with MetS.
In 3T3-L1 cell cultures, curcumin treatment 
suppressed the differentiation of preadipocytes to 
adipocytes and decreased the expression of PPAR-γ 
(52). In the same cells, curcumin decreased inflam-
matory responses by inhibiting the release of mono-
cyte-chemoattractant protein-1 (MCP-1) (53). In pre-
clinical studies, curcumin use showed beneficial ef-
fects on the body weight. In one experiment, two-
week pretreatment with curcumin and related com-
pounds (curcuminoids) reduced the fat accumula-
tion in epididymal adipose tissue and suppressed lip-
id accumulation in the liver, probably due to stim-
ulated β-oxidation of free fatty acids. Other stud-
ies have revealed that curcumin administration in 
HFD-induced obesity and ob/ob obese mice sup-
pressed inflammation, increased adiponectin release 
and improved insulin resistance (54-55). 
Despite the numerous animal studies demon-
strating the anti-obesity effects of curcuminoids, the 
number of clinical studies is limited. Mohammadi et 
al. were the first to investigate their effects in obese 
subjects. In these patients, the BMI and TG levels 
were significantly reduced (56). Later, other authors 
confirmed the weight-reducing potential of these 
compounds and supposed that acting as anti-inflam-
matory agents they improve insulin resistance (57-
58). A meta-analysis from 2019 showed that curcum-
in intake effectively reduced body weight, BMI, waist 
circumference, leptin levels, and increased adiponec-
tin levels (59). It is worth mentioning that chronic 
curcumin consumption might lead to hepatotoxici-
ty, skin allergic eruptions or gastrointestinal distress 
(60). Although the Mediterranean diet (abundant in 
PPs) is associated with weight loss, most trials found 
no effect of PPs on body weight and lipid profile in 
subjects with MetS. (61-66).
The mechanisms of anti-obesity and antihyper-
lipidemic effects of polyphenols are summarized in 
Table 2.
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Polyphenols and Insulin Resistance/
Hyperglycemia
In states of insulin resistance, insulin is not able 
to lower the blood glucose level. This occurs due to 
the inability of the hormone: (1) to transport glucose 
from the systemic circulation into insulin-dependent 
tissues through GLUT-4-mediated glucose trans-
port; (2) to induce glycogen synthesis; (3) to suppress 
glycogen breakdown; (4) to inhibit gluconeogenesis; 
(5) to activate lipogenesis; (6) to suppress lipolysis. 
Studies have demonstrated that PPs can improve IR 
and glycemic control (78).
Meta-analyses and systematic reviews showed 
that foods rich in (-)-epicatechin and EGCG such 
as cocoa and green tea increased insulin sensitivity 
and decrease blood glucose levels. Insulin levels and 
IR (measured with Homeostatic Model Assessment-
Insulin Resistance—HOMA-IR; ≥ 2.5 is considered 
a marker for IR) were significantly lower after reg-
ular consumption of dark chocolate rich in EGCG. 
Continuous regular daily consumption of green tea 
(15 to 60 days) was associated with improved insu-
lin profile but such an effect was not observed after 
a short exposure (< 15 days). Another systemic re-
view showed that anthocyanin intake significantly 
reduced both plasma insulin levels and HOMA-IR in 
adults. Researches also confirmed the role of pheno-
lic acids in enhancement of insulin effects but again 
only in high doses. The data concerning the effects of 
stilbenes, quercetin and hesperidin on insulin sensi-
tivity are also conflicting (78).
The PPs act by different mechanisms to im-
prove insulin resistance and glucose homeosta-
sis (78). First, they decrease carbohydrate degrada-
tion and absorption in the small intestine. There 
are numerous publications which demonstrate the 
α-amylase and α-glucosidase-inhibiting activities of 
different PPs. A few in vitro experiments have dem-
onstrated their GLUT2 and SGLT2-inhibiting activi-
ties (79). Second, some PPs affect glucose transport. 
Affected Process Mechanisms Reference
Food intake (suppressed) Increased release of cholecystokinin (67)
Calorie loss/Energy expenditure 
(increased)
Inhibition of pancreatic lipase and lipid absorption in 
the small intestine; upregulation of UCPs (68-69)
Lipogenesis (inhibited) AMPK-activation (70)
Lipolysis (inhibited) Increased expression of AMPK, HSL, CPT-1, UCP-1/2, SIRT1 (24, 69-71) 
Fatty acid β-oxidation (stimulated)
Upregulation of HSL, CPT-1, UCP-1/2, adiponectin; 
decrease in the level of malonyl-CoA (inhibitor of fatty 
acid β-oxidation)
(69, 71-73)
Adipocyte differentiation and growth 
(inhibited)
Downregulation of PPAR-γ, C/EBPα; adipocyte cell 
cycle arrest (24)
Intestinal cholesterol absorption 
(inhibited)
Inhibition of intestinal cholesterol influx transporter 
(NPC1L1) (74)
Cholesterol synthesis (inhibited) Inhibition of HMG-CoA reductase and SREBP1c (24)
Cholesterol and bile acid fecal 
excretion (stimulated) Decreased micellar solubility of cholesterol (75)
Reverse cholesterol transport—
from peripheral tissues to liver 
(stimulated)
Upregulation of SR-BI, ABCA1, ABCG1 and ApoA1 (24, 76-77) 
Legend: ABCA1—ATP-binding cassette transporter subfamily A member 1;  ABCG1—ATP-binding cassette transporter subfamily G 
member 1; AMPK—adenosine monophosphate kinase; ApoA1—apolipoprotein A1; C/EBPα—CCAT (cytosine-cytosine-adenosine-
adenosine-thymidine)-enhancer-binding protein-alpha; CPT-1—carnitine palmitoyltransferase 1; HSL—hormone-sensitive lipase; 
NPC1L1—Niemann-Pick C1-Like 1 protein; PPAR-γ—peroxisome proliferator activated receptor-gamma; SIRT1—sirtuin 1; SR-BI—
scavenger receptor class B type I (HDL receptor); SREBP1c—sterol regulatory element-binding protein-1; UCP—uncoupling protein.
Table 2. Mechanisms of the anti-obesity and lipid-lowering effects of polyphenols
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Quercetin and green tea catechins stimulate GLUT-
4-mediated glucose transport in insulin-dependent 
tissues. Furthermore, quercetin increases the expres-
sion of GLUT-4. Third, PPs are potential enhancers 
of insulin secretion and insulin-signaling pathways. 
For instance, vanillic acid stimulates PKA and sup-
presses KATP in pancreatic β-cells and promotes in-
sulin release; phenolic acids, genistein, and anthocy-
anins promote postprandial glucagon-like peptide 1 
(GLP-1) secretion; catechins inhibit dipeptidyl pepti-
dase-4 (DPP-4, an enzyme responsible for the inacti-
vation of GLP-1) and prolong the plasma half-life of 
GLP-1;quercetin increases the activity of insulin re-
ceptor substrate-1 (IRS-1) and enhances GLUT-4 ex-
pression (80-83). PPs such as cinnamic acid, catechin, 
and EGCG have additionally demonstrated gluco-
neogenesis-inhibiting effects (84-85). Other probable 
insulin-sensitizing mechanisms are the powerful an-
tioxidant and anti-inflammatory effects of PPs. 
A review from 2018 (86) summarizes that poly-
phenolic compounds inhibit NF-κB expression, sup-
press mitogen-activated protein kinase (MAPK), 
mammalian target of rapamycin complex-1 
(mTORC1), JAK/STAT and phospholipase A2-medi-
ated inflammatory pathways. They exert an antiox-
idant effect by stimulating the endogenous antioxi-
dant enzymes and inhibiting reactive oxygen species 
production. All these effects improve insulin resis-
tance and lower blood glucose level.
Polyphenols and Arterial Hypertension
High arterial blood pressure is considered an 
important risk factor in patients with MetS. There is 
a rising number of studies showing a correlation be-
tween PP intake and arterial blood pressure lower-
ing. For example, a cross-sectional study among 2618 
individuals conducted in Iran concluded that high 
PP consumption was inversely associated with sys-
tolic (SBP) and diastolic (DBP) blood pressure (87). 
Another study among 2573 patients with type 2 dia-
betes mellitus confirmed that high PP intake was as-
sociated with lower mean SBP and DBP compared to 
the individuals with lower PP intake (88). Meta-anal-
yses showed that a significant blood pressure-lower-
ing effect was observed with dietary consumption of 
isoflavones, anthocyanins, phenolic acids, and lig-
nans. Such an effect was demonstrated also for soy-
beans, berries, pomegranate juice, coffee, tea, and 
seeds (sesame, flaxseeds) (89-95). In subjects with 
MetS, two-month dietary intake of chokeberry (Aro-
nia melanocarpa) significantly decreased blood pres-
sure (96). A similar result was achieved by cinnamon 
(97). Quercetin also had a beneficial effect on blood 
pressure (98). 
Despite the numerous studies demonstrating 
the positive impact of PPs on blood pressure, the 
data are not conclusive and some studies have yield-
ed conflicting results. For instance, a meta-analysis 
concluded that blueberry supplementation (anthocy-
anins, respectively) did not lower the arterial blood 
pressure (99). Another meta-analysis showed that soy 
isoflavones decreased SBP but not DBP and the ef-
fects were observed in hypertensive but not in nor-
motensive individuals (100). In one trial, resveratrol 
supplementation did not improve blood pressure in 
individuals with MetS, it even caused slight increase 
in DBP (101). These contradictory results might be 
associated with the pharmaceutical formulations of 
the extracts (pills), or with the duration of the trials 
(acute or chronic), or both. 
The mechanisms involved in the blood pres-




Flavonoids Inhibition of endothelial NADPH oxidase and increased release of NO; impairment of ACE/AT II-receptor activity (102-103)
Isoflavones Interaction with estrogen-response element and increased NO production (104)
Anthocyanins Regulation of NOS; inhibition of endothelial cell apoptosis (102-103, 105)
Table 3. Mechanism of antihypertensive effects of polyphenols
Legend: ACE—angiotensin-converting enzyme; AT II—angiotensin II; NO—nitric oxide; NOS—nitric oxide synthase. 
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CONCLUSION
Polyphenols are ubiquitously present in the na-
ture. High intake of polyphenol-rich foods is inverse-
ly associated with the incidence of a number of clini-
cal conditions (cardiovascular diseases, type 2 diabe-
tes, obesity, non-alcoholic fatty liver disease, cancer) 
including metabolic syndrome. Literature data col-
lected from scientific databases review the promis-
ing effects of polyphenols in improving the biochem-
ical and clinical abnormalities associated with meta-
bolic syndrome. However, larger, more precise, bet-
ter controlled clinical trials are necessary to demon-
strate their benefits in clinical practice.
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